GILD Stock Analysis: Buy, Sell, or Hold?
GILD - Gilead Sciences Inc
$130.21
-1.07 (-0.82%)
▼
5d:
+0.7%
30d:
+3.37%
90d:
-0.48%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 04, 2026
TODAY
Smart Money Accumulation
None View Scanner →
Strength: 9.1/10
Get Alerted When GILD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GILD shows positive signals but monitor for confirmation. Market pricing in 1.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GILD shows positive signals but monitor for confirmation. Market pricing in 1.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$192.72
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$119.67
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GILD is currently trading at $130.21, which is considered fair relative to its 30-day fair value range of $126.83 to $133.86. The stock's valuation (Forward PE: 13.5) is in line with its historical norms (14.3). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This pessimistic expectation contrasts with the company's recent 54.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GILD is in a downtrend. The price is currently testing key support at $127.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $157.15 (+20.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GILD is in a downtrend. The price is currently testing key support at $127.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $157.15 (+20.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$126.83 -
$133.86
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.7% below Wall St target ($157.15)
Trading Range Analysis
30-Day Trading Range
$126.83 -
$133.86
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$127.61
Resistance Level
$136.26
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.54
Wall Street Target
$157.15
(+20.7%)
Revenue Growth (YoY)
4.4%
Earnings Growth (YoY)
54.8%
Profit Margin
31.0%
Valuation Discount vs History
-1.8% cheaper
PE vs Historical
13.5 vs 14.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.8%
(market-implied from PE analysis)
1-Year Target
$127.87
(-2%)
2-Year Target
$125.56
(-4%)
3-Year Target
$123.30
(-5%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
$130.25
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.06 | Current EPS (TTM): $7.27
Bull Case
$191.06
(+47%)
Analyst growth 32.3%, PE expands to 19.9
Base Case
$173.69
(+33%)
Market implied 32.3%, PE stable at 18.1
Bear Case
$89.27
(-31%)
Severe decline -20.0%, PE contracts to 15.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.5 to 14.3
Stabilization Target:
$137.54
(+5.6%)
PE Expansion Potential:
+5.6%
Share & Embed Analysis
Last updated: August 03, 2026 1:28 AM ET
Data refreshes hourly during market hours. Next update: 2:28 AM
Data refreshes hourly during market hours. Next update: 2:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GILD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew D Dickinson
SELL
3000 shares
2026-04-15
Johanna Mercier
SELL
3000 shares
2026-04-15
Andrew D Dickinson
SELL
3000 shares
2026-03-16
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$234 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 52 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$135 | 56 HOLD |
Advanced GILD Option Strategies
Professional options setups generated by AI based on today's GILD price and gamma walls.
